Official Title: “Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium.”

The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis).

The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety.

Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: Organogel of naftifine, 2%
• Drug: Organogel of terbinafine, 2%
• Drug: Organogel of naftifine, 6%
• Drug: Organogel of terbinafine, 6%

Primary Measures

• Quanitative improvement in toenail appearance.
• Assessment of dermatophyte culture and KOH examination.
• Frequency and severity of adverse events.

Secondary Measures

• Time to achieve 90% and 100% clearance of fungus from nail.
• Assessment of treatment success.
• Assessment of mycological success.

Inclusion Criteria:

• clinical diagnosis of distal subungual tinuea unguium of one great toenail.
• between 20 - 65% infected area for target nail
• 2 mm of clear nail proximally on target nail
• positive dermatophyte culture and positive KOH test
• able to sign informed consent
• understand requirements of study
• females must be post-menopausal or agree to use approved contraceptives throughout the study

Exclusion Criteria:

• patients with nails infected with organisms other than dermatophytes
• patients with proximal subungual tinea unguium
• patients with spikes of disease extending to nail matrix
• patients with more than 5 infected nails
• patients with confounding problems/ abnormalities of target nail
• patients with screening lab values more than 20% of normal
• patients with known hypersensitivity to test material components
• patients requiring systemic medications that may interfere with study
• patients with a poor history of compliance with study requirements

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: MediQuest Therapeutics

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00253305

Study ID Number: MQT-05-001

ClinicalTrials.gov Identifier: NCT00253305

Health Authority: United States: Food and Drug Administration